An interventional study of Fecal microbiota transplantation (FMT) in Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC) and Metabolic Syndrome (MetS), sponsored by Catholic University of the Sacred Heart. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Catholic University of the Sacred Heart · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Colitis, Ulcerative with a site in Italy — 47 open to participants now, 76 under way, 27 of them phase 3. Colitis, Ulcerative · Italy.
Among the 209 studies in Colitis, Ulcerative with a site in Italy, this one is the 125th largest by planned enrollment of the 175 interventional ones that give a count, is one of 17 that started in 2026, is one of 24 with no phase, reaches primary completion later than 65 of the 75 other live ones, and was the 179th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →47 of the 209 studies in Colitis, Ulcerative with a site in Italy are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Italy, United States, Canada and 9 more countries
Ages 18–75
Pfizer · Sites in Italy, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Italy, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–80
University of Padova · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 77 · Phase 3 73 · Phase 4 9
First in 2003; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 182 across the 175 interventional studies, 279 across the 34 observational. Of the 123 that completed or were terminated, 74 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 209 have an industry lead sponsor. The 10 most frequent:
Catholic University of the Sacred Heart is the lead sponsor of 237 studies on the registry; 29 are open to participants now.
Catholic University of the Sacred Heart has 3 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
23 of the studies in Colitis, Ulcerative with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 23 to your calendar (.ics) → With an account.
Among the 209 studies in Colitis, Ulcerative with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS). Microbiota therapeutics, particularly fecal microbiota transplantation (FMT), show promise-achieving \~90% cure rates in rCDI-but demonstrate variable efficacy in chronic conditions. Microbiome engraftment appears critical for FMT success, yet consistent predictors remain lacking. A meta-analysis of 20 FMT studies by our group and the Segata Lab linked engraftment to clinical response across diseases, with taxon-specific patterns and ML-based predictability. While viral, fungal, host immune, genetic, and metabolic factors may affect engraftment, their roles are not well-defined. Key unresolved questions include the interplay among host factors, microbial strains, and metabolites, their influence on engraftment, and impact on clinical outcomes. This study aims to unravel microbiome engraftment dynamics and link them to therapeutic response.
Gut microbiota regulates key functions in humans, i.e. immunity and metabolism, and is a pathogenic pathway of many disorders, including recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS). Microbiota therapeutics (MT) have raised high expectations without comparable results. Among MT, fecal microbiota transplantation (FMT), the transfer of healthy donor feces to a recipient with a microbiome-associated disease, has achieved high (nearly 90%) cure rates of rCDI but lower and less consistent results in chronic disorders, i.e. UC or MetS. Clinical and microbial features seem to be related with FMT outcomes, but consistent predictors are not available.
Donor-recipient microbiome engraftment may be critical for the clinical success of FMT. In a pooled meta-analysis of 20 FMT studies in different diseases by our group and the Segata Lab , donor recipient microbiome engraftment was associated with clinical response regardless of disease, differed among bacterial taxa, and was predicted by machine learning (ML). Other factors could influence engraftment, but evidence is unclear. Virome and fungome, have been linked to FMT success, but their engraftment kinetics is unknown. Host factors, i.e. genetics, gut immunity and microbial metabolites are supposed to play a role in engraftment, but supporting data are still absent.
Crucial issues of the engraftment dynamics remain still unsolved, including 1) which are the interactions among host factors, microbial strains, and products during FMT; 2)whether and how they influence engraftment and 3) clinical outcomes.Our aim is to disentangle the dynamics of microbiome engraftment and correlate them to clinical outcomes.
OBJECTIVES
Primary objectives - To assess the longitudinal multidomain interactions of host and microbiome variables and their influence on microbial engraftment
Secondary Objectives
- To assess the longitudinal multidomain interactions of host and microbiome variables and their influence on clinical outcomes
Endpoints
Primary - The longitudinal evaluation of multidomain interactions of host and microbiome variables throughout a multi-omics approach at 90 days after the last FMT
Secondary
- The longitudinal evaluation of multidomain interactions of host and microbiome variables throughout a multi-omics approach at 7,30,180,360 days after the last FMT
Procedures:
Baseline assessment
At baseline enrolled patients will be evaluated by the gastroenterology staff and endocrine and metabolic Unit staff of the Fondazione Policlinico Universitario A. Gemelli IRCCS and their demographic, clinical characteristics and laboratory data will be recorded, specifically:
In addition, the following data for patients in all cohorts will be collected:
After the baseline assessment, all patients will undergo to the FMT combined (colonoscopy + capsules) procedure.
Follow-up visits
All patients will undergo follow-up visits at day 7, 30, 90, 180, 360 after the last FMT.
At each time point, the gastroenterology staff and endocrine and metabolic unit staff of the Fondazione Policlinico Universitario A. Gemelli IRCCS, will assess the same items assessed at baseline (demographic, clinical characteristics including disease activity, and laboratory data) and the same blood and stool sample will be collected. Moreover, a stool sample will be collected after the pre-conditioning with nonabsorbable antibiotics.
Gut biopsies will be collected at day 30,180 and 360 after the last FMT.
Treatment
Patients will receive a first donor FMT by colonoscopy, after a pre-conditioning with vancomycin and neomycin + bacitracin for 3 days, because data from our group show that pre-FMT antibiotics are associated with higher rates of microbial engraftment. Then they will receive two cycles, respectively after 3 and 7 days after colonoscopy - FMT, of frozen donor FMT capsules (15 capsules b.i.d. per 3 days). Patients will always receive feces from the same donor.
Donors Recruitment
Potential donor candidates will be evaluated by the gastroenterology staff of the Fondazione Policlinico Universitario A. Gemelli IRCCS, following protocols recommended by international guidelines and according to the recent recommendations imposed by the reorganization of faecal microbiota transplant during the COVID-19 pandemic.
In addition, in relation to the national and international spread of human cases of monkey pox, according to the reports of the European Centre for Disease Prevention and Control (ECDC) and the FDA and as indicated in the circulars of the General Directorate for Health Prevention of the National Ministry of Health of 25/5/2022 (Prot. DGPREV 0026837), of 02/08/2022 (Prot. DGPREV 0034905) and in The National Transplants Center note of 07/06/2022 (Prot. ISS 0021745).
Collection and storage of stool and blood samples
Stool samples will be collected in donors and in patients at baseline and at each follow-up visit, using a Zymo buffer, to preserve feces at room temperature for up to 48 hours. Fecal samples will be stored at -80°C and assigned de-identified IDs. Blood samples will be collected in donors and in patients at each timepoint (1 mL of whole blood per sample), centrifuged at 2000 rpm for 15 minutes for serum collection, stored at a temperature of -80°C. Both stool and blood samples will be stored until the end of the clinical study (after the end of the follow-up of the last enrolled patient). Then, blood samples will be used for the analysis of human genes, associated with microbiome and beta diversity, while stool samples will be used for microbiome analysis.
RNA extraction
Total RNA will be prepared by the RNeasy kit (Qiagen) based on manufacturer's instructions. Samples are first lysed and then homogenized. Ethanol is added to the lysate to provide ideal binding conditions. The lysate is then loaded onto the RNeasy silica membrane and RNA binds to the silica membrane, and all contaminants are efficiently washed away. 100 ng/μl of RNA will be analyzed for RNA integrity and then interrogated by microarray using Affymetrix technology. Fold-change data will be calculated for each gene from the microarray analysis, comparing expression among different groups of samples. Data set will be trimmed to include only those genes showing at least a ±1.5-fold change relative to the C. difficile infection cohort, which will be then submitted to Ingenuity Pathway Analysis (IPA, Qiagen) for unsupervised clustering analysis. Potential gene networks will be identified by the Global Molecular Network algorithm.
Genome extraction and shotgun metagenomic sequencing
DNA extraction will be performed by using the Dneasy PowerSoil Pro Kit (QIAGEN, Germany) according to the manufacturer's procedures. DNA concentration will be measured with Qubit (Thermo Fisher Scientific, USA), and DNA will be then stored at - 20°C. Sequencing libraries will be prepared using the Illumina® DNA Prep (M) Tagmentation kit (Illumina, California, USA) following the manufacturer's guidelines.
Shotgun metagenomic sequencing will be performed on the Illumina NovaSeq platform.
A >7.5Gb/sample of 150nt paired end reads (insert size \~150nt) will be generate. This will be sufficient to cover at 2x a 4Mb bacterial, fungal, and viral genome present at an abundance of 0.1% after accounting for human DNA reads removal, and to detect with our markerbased strategy organisms at abundances as low as 0.01%. All the above procedures have been extensively validated. As gut mycobiome is hardly detected by WGS, it will be assessed also by sequencing the ITS2 region and the 18SrRNA gene.
Metagenome quality control and pre-processing
Newly generated shotgun metagenomic sequences will be pre-processed and quality controlled using the pipeline available at https://github.com/SegataLab/preprocessing.
Reads will be quality-controlled and those of low quality (quality score 2 ambiguous nucleotides were removed with Trim Galore. Contaminant and host DNA will be identified with Bowtie2 using the parameter -sensitive-local, allowing confident removal of the phiX 174 Illumina spike-in and human reads (hg19 human genome release). Remaining high-quality reads will be sorted and split to create forward reverse and unpaired reads output files for each metagenome.
Microbiome taxonomic profiling
Microbiome taxonomic profiling will be performed following the general guidelines and relying on the bioBakery computational environment. The taxonomic profiling and quantification of organisms' relative abundances of all metagenomic samples will be quantified using MetaPhlAn 3.0 (species-level profiling) and StrainPhlAn 3 (strain-level profiling).
Metatranscriptomic, metabolomic and metaproteomic analysis
Metatranscriptomics (MTR), metabolomics (MTB) and metaproteomics (MTP) will be performed in stool samples. For a metatrascriptomic analysis sample preparation will use the most up-to-date and validated protocol for mRNA fraction enrichment by rRNA depletion as per the Illumina protocols. cDNA libraries will be synthetized, and dedicated pipelines will follow.
Furthermore, volatile, and nonvolatile metabolites will be assessed in stool samples to perform a metabolomic analysis. The untargeted analysis will be carried out by GC-MS coupled to solid phase microextraction (SPME) (Agilent Technologies 7890B GC, coupled to a 5977A mass selective detector), 1H-NMR (50), and by LC-MS/MS based technology by pipelines optimized in house. Data will be analyzed with MetaboAnalyst, SCIEX OS, MATLAB toolbox, and R and Phyton scripts. Metaproteomics required a specific procedure as follow, microbial cells will be purified from 300 mg of each stool sample and cells lysis will be performed adding 4% SDS (w/v) lysis buffer followed by incubation at 95 °C for 10 min with agitation and 3 rounds of sonication. After protein quantification, equal amount of each sample will be trypsin digested by FASP protocol. The tryptic peptide mixtures will be analyzed by nanoLCESI-MS/MS acquisition on a high resolution mass spectrometer. Data will be analyzed with MetaLab platform and ad-hoc Python scripts.
Cytokine Multiplex Immunoassay
Through Multiplex Bead analysis for the assessment of specific cytokine in biopsy samples will be perform, following manufacturer's instructions. IL-1b, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-g, IP-10, MCP-1, MIP-1a, PDGF-bb, MIP-1b, RANTES, TNF-a, VEGF will be analyzed. Flow cytometry will be also performed in colonic biopsies to identify the specific phenotype of immune cells localized in the mucosal samples.
Machine learning analysis
Machine learning models will be used to identify and reproducibly characterize responder and non-responder profiles. In a Python 3.9 environment using scikit-learn (ver. 0.22.1), two unsupervised ML algorithm, K-means and Agglomerative Hierarchical Clustering, will be used for creating patient clusters based on baseline microbiome, cytokine signature and clinical features, in order to assess whether ML may identify distinct subgroups of microbiome and cytokine profiles associated with clinical response.
Statistical Analysis
Sample size calculation
This study is exploratory in nature and sample size calculation is no hypotheses-driven. A size of 30 patients in each group (total sample size 3*30=90 patients) will be considered. As a general approach 30 patients will have an 80% power of detecting large effect size (f=0.40) at a significance level of 5%.
Data Analysis
Descriptive statistics will be used to analyse baseline and follow-up variables.
Data will be presented as mean and standard deviation (SD) or as median and first and third quartile according to the normality of data distribution. Qualitative variables will be summarized by absolute and relative frequencies (percentage). All statistics will be tabulated according to groups (UC, rCDI, MetS) and to different timepoints. According to the data distribution an approach based on analysis of variance or Kruskal-Wallis/Friedmann test will be employed. Due to the high number of variables resulting from analyses and to the exploratory nature of this project no adjustment for multiple testing will be considered. Machine-Learning algorithms will deal with the complexity of the multidimensional data matrix.
SAFETY REPORTING
No specific serious adverse events are expected. Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the surveillance protocol. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded and reported to the coordinating investigator.
A serious adverse event is any untoward medical occurrence or effect that at any dose:
ETHICS
The study protocol must be approved by the ethics committee CET Lazio Area 3 and by the Italian National Transplant Centre will be registered at ClinicalTrials.gov. The study will be conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) Statement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Coorte: Patients affected by Ulcerative Colitis
Coorte: Patients affected by metabolic syndrome
Coorte: Patients affected by rCDI
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with recurrent C. difficile infection (rCDI) will be recruited among those referred to the Digestive Disease Centre (CEMAD) of the Fondazione Policlinico Universitario A. Gemelli IRCCS. Patients with all inclusion criteria and none of the exclusion criteria will be considered for this study.
Other: Fecal microbiota transplantation (FMT)
Patients with Ulcerative Colitis (UC) will be recruited among those referred to the Digestive Disease Centre (CEMAD) of the Fondazione Policlinico Universitario A. Gemelli IRCCS. Patients with all inclusion criteria and none of the exclusion criteria will be considered for this study.
Other: Fecal microbiota transplantation (FMT)
Patients with metabolic syndrome (MetS), will be recruited among those referred to the Digestive Disease Centre (CEMAD) and to the Endocrine and Metabolic Diseases Unit of the Fondazione Policlinico Universitario A. Gemelli IRCCS.
Other: Fecal microbiota transplantation (FMT)
Patients will receive a first donor FMT by colonoscopy, after a pre-conditioning with vancomycin and neomycin + bacitracin for 3 days, because data from our group show that pre-FMT antibiotics are associated with higher rates of microbial engraftment. Then they will receive two cycles, respectively after 3 and 7 days after colonoscopy - FMT, of frozen donor FMT capsules (15 capsules b.i.d. per 3 days). Patients will always receive feces from the same donor.
Longitudinal Analysis of Host-Microbiome Interactions Driving Microbial Engraftment
To assess the longitudinal multidomain interactions of host and microbiome variables and their influence on microbial engraftment. Microbiome taxonomic profiling will be performed following the general guidelines and relying on the bioBakery computational environment. The taxonomic profiling and quantification of organisms' relative abundances of all metagenomic samples will be quantified using MetaPhlAn 3.0 (species-level profiling) and StrainPhlAn 3 (strain-level profiling). Metatranscriptomics (MTR), metabolomics (MTB) and metaproteomics (MTP) will be performed in stool samples. Through Multiplex Bead analysis for the assessment of specific cytokine in biopsy samples will be perform, following manufacturer's instructions. Flow cytometry will be also performed in colonic biopsies to identify the specific phenotype of immune cells localized in the mucosal samples.
Time frame: 60 months
Longitudinal Analysis of Host-Microbiome Interactions and Their Impact on Clinical Outcomes
A longitudinal multidomain analysis will investigate host-microbiome interactions using taxonomic profiling, metatranscriptomics, metabolomics, and metaproteomics in stool samples. Cytokine profiling in biopsy samples will be performed via Multiplex Bead analysis. These variables will be correlated with clinical outcomes, including disease activity in UC patients (Mayo score), insulin sensitivity in MetS patients (Matsuda and OGIS indices post-OGTT), and clinical features such as diarrhea and fecal C. difficile toxin in recurrent CDI cases.
Time frame: 60 months
Plan to share: Yes — De-identified individual participant data will be shared upon reasonable request for academic research purposes, following approval of a data access proposal and signing of a data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Access criteria: Data will be given upon reasonable request to the PI.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2029, 32 months after the start.
Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 32 months is close to that.
Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Catholic University of the Sacred Heart →